Search results
Showing 16 to 30 of 53 results for trastuzumab
NICE is unable to make a recommendation on trastuzumab deruxtecan (Enhertu) for treating hormone receptor-positive HER2-low metastatic breast cancer in adults after 2 or more endocrine treatments. This is because the company did not provide an evidence submission.
Show all sections
Sections for TA1112
NICE is unable to make a recommendation on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after a previous anti-HER2-based regimen in adults. This is because Daiichi Sankyo UK did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA879
Awaiting development Reference number: GID-TA11723 Expected publication date: TBC
Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer (TA569)
Evidence-based recommendations on pertuzumab (Perjeta) for adjuvant treatment of HER2-positive early stage breast cancer in adults.
Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer (TA424)
Evidence-based recommendations on pertuzumab (Perjeta) for treating HER2-positive breast cancer that is locally advanced, inflammatory, or early-stage with a high risk of recurrence, in adults.
Early and locally advanced breast cancer: diagnosis and management (NG101)
This guideline covers diagnosing and managing early and locally advanced breast cancer. It aims to help healthcare professionals offer the right treatments to people, taking into account the person's individual preferences.
Oesophago-gastric cancer: assessment and management in adults (NG83)
This guideline covers assessing and managing oesophago-gastric cancer in adults, including radical and palliative treatment and nutritional support. It aims to reduce variation in practice through better organisation of care and support, and improve quality of life and survival by giving advice on the most suitable treatments depending on cancer type, stage and location.
Awaiting development Reference number: GID-TA11110 Expected publication date: TBC
Awaiting development Reference number: GID-TA11659 Expected publication date: 13 May 2027
Awaiting development Reference number: GID-TA11403 Expected publication date: TBC
Awaiting development Reference number: GID-TA11706 Expected publication date: TBC
Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227]
In development Reference number: GID-TA11228 Expected publication date: TBC
Discontinued Reference number: GID-TA10591
Discontinued Reference number: GID-TA11318
Awaiting development Reference number: GID-TA11487 Expected publication date: TBC